THE COMPETING RISK APPROACH FOR PREDICTION OF PREECLAMPSIA.
The established method of assessing the risk for development of preeclampsia (PE) is to identify risk factors from maternal demographic characteristics and medical history; in the presence of such factors the patient is classified as high-risk and in their absence as low-risk. Although this approach is simple to perform, it has poor performance of predicting PE and does not provide patient-specific risks. This review describes a new approach which allows estimation of patient-specific risks of delivery with PE before any specified gestational age by maternal demographic characteristics and medical history with biomarkers obtained either individually or in combination at any stage in pregnancy. In the competing risks approach every woman has a personalized distribution of gestational age at delivery with PE and whether she develops PE or not before a specified gestational age depends on competition between delivery before or after development of PE. The personalized distribution comes from the application of Bayes theorem to combine a prior distribution, determined from maternal factors, with likelihoods from biomarkers. As new data become available, what were posterior probabilities take the role as the prior and data collected at different stages are combined by repeating the application of Bayes theorem to form a new posterior at each stage allowing for dynamic prediction of PE. The competing risk model can be used for precision medicine and risk stratification at different stages of pregnancy. In the first-trimester, the model has been applied to identify a high-risk group that would benefit from preventative therapeutic interventions. In the second-trimester, the model has been used to stratify the population into high- intermediate- and low-risk groups in need of different intensities of subsequent monitoring thereby minimizing unexpected adverse perinatal events. The competing risks model can also be used in surveillance of women presenting to specialist clinics with signs or symptoms of hypertensive disorders; combination of maternal factors and biomarkers provide patient-specific risks for PE leading to personalized stratification of the intensity of monitoring with risks updated on each visit on the basis of biomarker measurements.